Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer

INVENTION NOVELTY

JHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.

VALUE PROPOSITION

Investigators have discovered a drug composition that could be used to inhibit and treat neoplastic diseases such as liver, colon, breast, brain or ovarian cancers.  It was found that M4N, which is nontoxic to normal cells at high concentrations, alters cancer cell metabolism in a way that synergistically enhances Sorafenib’s ability to induce cancer cell death.   

The current invention aims to provide:

• A new drug treatment for various types of cancer

TECHNICAL DETAILS

• Investigators found M4N and Sorafenib are strongly synergistic.  This synergy resulted in a strong dose reduction index which means it has reduced drug toxicity while desired efficacy is maintained.  Sorafenib’s  cancer cell toxicity was increased by 70% when combined with M4N.
• Scientists showed the combination of M4N and Sorafenib is able to arrest tumor growth and increase tumor survival in mice with no adverse effects. 
• Investigators’ drug combination was effective at killing cancer cells from pancreas, breast, colon, pharynx, thyroid, brain, ovarian, renal and bladder cancer cell lines

STAGE OF DEVELOPMENT

Drug combination has been tested on cancer cell lines and in mouse tumor models, showing efficacy in killing cancer cells and increasing survival rates.

PUBLICATIONS & PATENT INFO:

US 20150018302



 

Category(s):